Literature DB >> 29458966

Have Clinical Trials Properly Assessed c-Met Inhibitors?

Veronica S Hughes1, Dietmar W Siemann2.   

Abstract

The c-Met/HGF pathway is implicated in cancer progression and dissemination. Many inhibitors have been developed to target this pathway. Unfortunately, most trials have failed to demonstrate efficacy. However, clinical trials have not adequately tested the concept of c-Met pathway inhibition due to the lack of appropriate patient selection criteria.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  c-Met; cancer; clinical trials; inhibitor

Mesh：

Substances：

Year:  2018        PMID： 29458966      PMCID： PMC5824436          DOI： 10.1016/j.trecan.2017.11.009

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  11 in total

1.  Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.

Authors:  P Peschard; T M Fournier; L Lamorte; M A Naujokas; H Band; W Y Langdon; M Park
Journal:  Mol Cell       Date:  2001-11       Impact factor: 17.970

Review 2.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

3.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Authors:  Garrett M Frampton; Siraj M Ali; Mark Rosenzweig; Juliann Chmielecki; Xinyuan Lu; Todd M Bauer; Mikhail Akimov; Jose A Bufill; Carrie Lee; David Jentz; Rick Hoover; Sai-Hong Ignatius Ou; Ravi Salgia; Tim Brennan; Zachary R Chalmers; Savina Jaeger; Alan Huang; Julia A Elvin; Rachel Erlich; Alex Fichtenholtz; Kyle A Gowen; Joel Greenbowe; Adrienne Johnson; Depinder Khaira; Caitlin McMahon; Eric M Sanford; Steven Roels; Jared White; Joel Greshock; Robert Schlegel; Doron Lipson; Roman Yelensky; Deborah Morosini; Jeffrey S Ross; Eric Collisson; Malte Peters; Philip J Stephens; Vincent A Miller
Journal:  Cancer Discov       Date:  2015-05-13       Impact factor: 39.397

4.  Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.

Authors:  Qian Xie; Robert Bradley; Liang Kang; Julie Koeman; Maria Libera Ascierto; Andrea Worschech; Valeria De Giorgi; Ena Wang; Lisa Kefene; Yanli Su; Curt Essenburg; Dafna W Kaufman; Tom DeKoning; Mark A Enter; Timothy J O'Rourke; Francesco M Marincola; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-27       Impact factor: 11.205

5.  Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.

Authors:  Pasi A Jänne; Sarada Gurubhagavatula; Beow Y Yeap; Joan Lucca; Patricia Ostler; Arthur T Skarin; Panos Fidias; Thomas J Lynch; Bruce E Johnson
Journal:  Lung Cancer       Date:  2004-05       Impact factor: 5.705

6.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

7.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

8.  Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.

Authors:  Apurva K Srivastava; Melinda G Hollingshead; Jennifer Weiner; Tony Navas; Yvonne A Evrard; Sonny A Khin; Jiuping Jay Ji; Yiping Zhang; Suzanne Borgel; Thomas D Pfister; Robert J Kinders; Donald P Bottaro; W Marston Linehan; Joseph E Tomaszewski; James H Doroshow; Ralph E Parchment
Journal:  Clin Cancer Res       Date:  2016-03-21       Impact factor: 12.531

9.  C-MET overexpression and amplification in gliomas.

Authors:  Yoonjin Kwak; Seong-Ik Kim; Chul-Kee Park; Sun Ha Paek; Soon-Tae Lee; Sung-Hye Park
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

10.  Retrospective Review of MET Gene Mutations.

Authors:  Maryam Zenali; James deKay; Zesheng Liu; Stanley Hamilton; Zhuang Zuo; Xinyan Lu; Rania Bakkar; Gordon Mills; Russell Broaddus
Journal:  Oncoscience       Date:  2015-05-14
View more
  15 in total

1.  Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.

Authors:  Maureen L Drakes; Patrick J Stiff
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

3.  Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition.

Authors:  Nezihi Murat Karabacak; Yu Zheng; Taronish D Dubash; Risa Burr; Douglas S Micalizzi; Ben S Wittner; Maoxuan Lin; Devon F Wiley; Valentine Comaills; Erin Emmons; Kira L Niederhoffer; Uyen Ho; Jacob Ukleja; Dante Che; Hannah Stowe; Linda T Nieman; Wilhelm Haas; Shannon L Stott; Michael S Lawrence; David T Ting; David T Miyamoto; Daniel A Haber; Mehmet Toner; Shyamala Maheswaran
Journal:  Cancer Res       Date:  2022-03-15       Impact factor: 13.312

Review 4.  Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement.

Authors:  Xing Huang; Enliang Li; Hang Shen; Xun Wang; Tianyu Tang; Xiaozhen Zhang; Jian Xu; Zengwei Tang; Chengxiang Guo; Xueli Bai; Tingbo Liang
Journal:  Front Cell Dev Biol       Date:  2020-05-06

5.  Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion.

Authors:  Veronica S Hughes; Dietmar W Siemann
Journal:  Oncotarget       Date:  2019-01-04

6.  TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.

Authors:  Marco Gymnopoulos; Oscar Betancourt; Vincent Blot; Ryo Fujita; Diana Galvan; Vincent Lieuw; Sophie Nguyen; Jeanette Snedden; Christine Stewart; Jose Villicana; Jon Wojciak; Eley Wong; Raul Pardo; Neki Patel; Francois D'Hooge; Balakumar Vijayakrishnan; Conor Barry; John A Hartley; Philip W Howard; Roland Newman; Julia Coronella
Journal:  Mol Oncol       Date:  2019-12-03       Impact factor: 6.603

7.  EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming.

Authors:  Fanyan Meng; Ling Wu; Lun Dong; Allison V Mitchell; C James Block; Jenney Liu; Haijun Zhang; Qing Lu; Won-Min Song; Bin Zhang; Wei Chen; Jiani Hu; Jian Wang; Qifeng Yang; Maik Hüttemann; Guojun Wu
Journal:  Nat Commun       Date:  2019-11-06       Impact factor: 14.919

8.  MET canonical transcript expression is a predictive biomarker for chemo-sensitivity to MET-inhibitors in hepatocellular carcinoma cell lines.

Authors:  Wafaa M Rashed; Mohamed A Kandeil; Mohamed O Mahmoud; Doha Maher; Sameera Ezzat; Mohamed H Abdel-Rahman
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-26       Impact factor: 4.553

9.  Machine Learning-Guided Prediction of Antigen-Reactive In Silico Clonotypes Based on Changes in Clonal Abundance through Bio-Panning.

Authors:  Duck Kyun Yoo; Seung Ryul Lee; Yushin Jung; Haejun Han; Hwa Kyoung Lee; Jerome Han; Soohyun Kim; Jisu Chae; Taehoon Ryu; Junho Chung
Journal:  Biomolecules       Date:  2020-03-08

Review 10.  Cyclic Peptide-Based Biologics Regulating HGF-MET.

Authors:  Hiroki Sato; Ryu Imamura; Hiroaki Suga; Kunio Matsumoto; Katsuya Sakai
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.